Karo Pharma Ab Stock Shares Outstanding
| KARBFDelisted Stock | USD 5.25 0.00 0.00% |
Karo Pharma AB fundamentals help investors to digest information that contributes to Karo Pharma's financial success or failures. It also enables traders to predict the movement of Karo Pink Sheet. The fundamental analysis module provides a way to measure Karo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Karo Pharma pink sheet.
Karo |
Karo Pharma AB Company Shares Outstanding Analysis
Karo Pharma's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Karo Pharma Shares Outstanding | 273.26 M |
Most of Karo Pharma's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Karo Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Karo Pharma AB has 273.26 M of shares currently outstending. This is 51.36% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 52.21% higher than that of the company.
Karo Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Karo Pharma's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Karo Pharma could also be used in its relative valuation, which is a method of valuing Karo Pharma by comparing valuation metrics of similar companies.Karo Pharma is currently under evaluation in shares outstanding category among related companies.
Karo Fundamentals
| Return On Equity | -0.0269 | |||
| Return On Asset | 0.0017 | |||
| Profit Margin | (0.05) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 273.26 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 88.29 % | |||
| Price To Earning | 262.50 X | |||
| Price To Book | 1.89 X | |||
| Price To Sales | 4.49 X | |||
| Revenue | 2.96 B | |||
| Gross Profit | 1.71 B | |||
| EBITDA | 761.36 M | |||
| Net Income | (17.45 M) | |||
| Cash And Equivalents | 33.24 M | |||
| Cash Per Share | 0.30 X | |||
| Total Debt | 5.58 B | |||
| Debt To Equity | 1.06 % | |||
| Current Ratio | 2.71 X | |||
| Book Value Per Share | 2.30 X | |||
| Cash Flow From Operations | 532.6 M | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 225 | |||
| Beta | 0.1 | |||
| Market Capitalization | 1.52 B | |||
| Total Asset | 12.59 B | |||
| Retained Earnings | (1.13 B) | |||
| Working Capital | 201 M | |||
| Current Asset | 288 M | |||
| Current Liabilities | 87 M | |||
| Net Asset | 12.59 B |
About Karo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Karo Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karo Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Karo Pharma AB information on this page should be used as a complementary analysis to other Karo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Karo Pink Sheet
If you are still planning to invest in Karo Pharma AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karo Pharma's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |